Primary aldosteronism
Conditions
Interventions
Gold Standard:adrenal venous sampling
Index test:68Ga-PentixaFor PET imaging
Sponsors
Zhongnan Hospital of Wuhan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Positive aldosterone to renin ratio (ARR) and positive confirmatory test; 2. The patients had signed informed consent before joining the clinical trial and were aged 18-70 years at the time of signing the informed consent.
Exclusion criteria
Exclusion criteria: 1. The patient refused 68Ga-PentixaFor PET/CT, AVS, CT examination or laparoscopic adrenal surgery; 2. Patients with suspected familial aldosteronism type 1 (FH-1) or type 3 (FH-3); 3. Patients with suspected adrenocortical carcinoma; 4. Patients with complications that seriously affect treatment or quality of life; 5. Patients need to take drugs that interfere with clinical studies; 6. The patient has any medical condition that the investigator believes will affect the clinical status; 7. Pregnant or lactating patients; 8. Patients with estimated glomerular filtration rate (eGFR) <40mL/min/1.73m^2; 9. The patient had other interference with the treatment of 68Ga-PentixaFor PET/CT and AVS.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| maximum standard uptake value;average standard intake value;aldosterone;renin;sensitivity;specificity;Youden's index;positive predictive value, PPV;negative predictive value, NPV; | — |
Countries
China
Contacts
Public ContactMeng Zhe
Zhongnan Hospital of Wuhan University
Outcome results
None listed